Business
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to
About this update from Nuvectis Pharma, Inc.
[{"type":"text","content":"Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatin\nFort Lee, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided highlights from the poster presentation that took place earlier today at the European Society for Medical Oncology (“ESMO”) Gynecological Cancers Congress. Two in vivo experiments in models of ARID1a-mutated ovarian carcinoma resulted in robust tumor growth inhibition (“TGI”) by NXP800 (70% in one model and 82% in the second model, including tumor regression in both models, versus 42% and 20% TGI with cisplatin with no tumor regression). Susana Banerjee, MBBA MA PhD, the Global Lead for the NXP800/ENGOTGYN5/GOG-3087 Phase 1b clinical trial in platinum resistant, ARID1a-mutated ovarian carcinoma and last author on the poster, commented: “There is a great need for new treatment options for women with ovarian cancer. We have known for a long time that ovarian cancer is a general term encompassing several diseases with different histologic and genetic characteristics that impact our patients’ likelihood to respond to standard of care chemotherapy and their overall prognosis. Our poster today showed the activity of NXP800 in two xenograft models of ARID1a-mutated ovarian carcinoma, a genetically defined subset of ovarian cancer. In patients with ovarian cancer, mutated ARID1a is mostly found in clear cell and endometrioid carcinomas, two diseases that are associated with poor outcomes in the platinum-resistant setting. I am excited about the Phase 1b clinical trial that is about to commence, given the clear need for new therapies for our patients and the potential of NXP800 in these disease settings.” About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is a clinical stage, oral small molecule currently in a Pha...